According to TipRanks.com, Wright is a 5-star analyst with an average return of 13.5% and a 68.7% success rate. Wright covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, Idexx Laboratories, and Quest Diagnostics.
Envista Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $21.83, representing a -5.6% downside. In a report released today, Piper Sandler also maintained a Hold rating on the stock with a $22.00 price target.
Envista Holdings’ market cap is currently $3.6B and has a P/E ratio of 21.00. The company has a Price to Book ratio of -3.39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The firm operates through the following segments; Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment & Consumables segments develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products. It offers dental consumables, equipment, and services to dental professionals. The company was founded on August 29, 2018 and is headquartered in Brea, CA.